Edgewise Therapeutics (EWTX) Operating Expenses (2020 - 2026)

Edgewise Therapeutics has disclosed Operating Expenses across 7 years of filings, most recently posting $54.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $54.1 million, up 17.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $199.6 million (up 17.36% YoY), and the FY2025 annual result was $191.4 million, up 20.51% from the prior year.
• Operating Expenses came in at $54.1 million for Q1 2026 at Edgewise Therapeutics, down from $56.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $56.0 million in Q4 2025 to a low of $14.8 million in Q1 2022.
• The 5-year median for Operating Expenses is $34.8 million (2024), against an average of $34.7 million.
• Across the five-year window, Operating Expenses surged 116.22% in 2022 and rose 11.82% in 2025, its largest moves.
• Edgewise Therapeutics' Operating Expenses stood at $22.1 million in 2022, then soared by 53.37% to $33.9 million in 2023, then soared by 34.49% to $45.5 million in 2024, then increased by 22.92% to $56.0 million in 2025, then slipped by 3.33% to $54.1 million in 2026.
• The last three Operating Expenses figures came in at $54.1 million (Q1 2026), $56.0 million (Q4 2025), and $46.9 million (Q3 2025), per Business Quant data.